A5081826448- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Virus-based gene therapy research
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- Immune cells in cancer
- RNA modifications and cancer
- Lung Cancer Research Studies
- Chemokine receptors and signaling
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- CRISPR and Genetic Engineering
- Cancer-related gene regulation
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- interferon and immune responses
- Glycosylation and Glycoproteins Research
- Cancer, Hypoxia, and Metabolism
- Genetic factors in colorectal cancer
- Prostate Cancer Treatment and Research
- Estrogen and related hormone effects
National Cancer Institute
2016-2025
National Institutes of Health
2015-2024
Center for Cancer Research
2015-2024
National Cancer Institute
2024
Cancer Institute (WIA)
2006-2022
Data Harbor (United States)
2015
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2014
Azienda Ospedaliera San Giovanni Addolorata
2012-2014
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2014
University of Rome Tor Vergata
2012-2014
Abstract Local radiation of tumor masses is an established modality for the therapy a range human tumors. It has recently been recognized that doses radiation, lower than or equal to those cause direct cytolysis, may alter phenotype target tissue by up-regulating gene products make cells more susceptible T-cell–mediated immune attack. Previously, we demonstrated increased Fas (CD95) expression in carcinoembryonic antigen (CEA)-expressing murine cells, which consequently enhanced their...
The switch of tumor cells from an epithelial to a mesenchymal-like phenotype [designated as epithelial-to-mesenchymal transition (EMT)] is known induce cell motility and invasiveness, therefore promoting metastasis solid carcinomas. Although multiple studies have focused on elucidating the signaling events that initiate this phenotypic switch, there has been so far no characterization pattern soluble mediators released by undergoing EMT, potential impact could remodeling microenvironment....
Metastatic disease is responsible for the majority of human cancer deaths. Understanding molecular mechanisms metastasis a major step in designing effective therapeutics. Here we show that T-box transcription factor Brachyury induces tumor cells epithelial-mesenchymal transition (EMT), an important progression primary tumors toward metastasis. Overexpression carcinoma induced changes characteristic EMT, including upregulation mesenchymal markers, downregulation epithelial and increase cell...
Certain chemotherapeutic regimens trigger cancer cell death while inducing dendritic maturation and subsequent immune responses. However, chemotherapy‐induced immunogenic (ICD) has thus far been restricted to select agents. In contrast, several drugs modulate antitumor responses, despite not classic ICD. addition, in many cases tumor cells do die after treatment. Here, using docetaxel, one of the most widely used agents, as a model, we examined phenotypic functional consequences that from...
HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), chemokine promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have demonstrated high serum IL-8 levels correlate with poor prognosis in many malignant tumors. Preclinical studies shown blockade may reduce mesenchymal features cells, making them less resistant to treatment.Fifteen patients...
Abstract Purpose: Natural killer (NK)-cell–based immunotherapy may overcome obstacles to effective T-cell–based such as the presence of genomic alterations in IFN response genes and antigen presentation machinery. All approaches be abrogated by an immunosuppressive tumor microenvironment present many solid types, including head neck squamous cell carcinoma (HNSCC). Here, we studied role myeloid-derived suppressor cells (MDSC) suppressing NK-cell function HNSCC. Experimental Design: The...
Recruitment of myeloid-derived suppressor cells (MDSCs) into tumors induces local immunosuppression in carcinomas. Here, we assessed whether SX-682, an orally bioavailable small-molecule inhibitor CXCR1 and CXCR2, could block tumor MDSC recruitment enhance T cell activation antitumor immunity following multiple forms immunotherapy. CXCR2+ neutrophilic MDSCs (PMN-MDSCs) were the most abundant myeloid subset within oral lung syngeneic PMN-MDSCs demonstrated greater suppression...
Collagens in the extracellular matrix (ECM) provide a physical barrier to tumor immune infiltration, while also acting as ligand for inhibitory receptors. Transforming growth factor-β (TGF-β) is key contributor shaping ECM by stimulating production and remodeling of collagens. TGF-β activation signatures collagen-rich environments have both been associated with T cell exclusion lack responses immunotherapy. Here, we describe effect targeting collagens that signal through leukocyte-associated...
Poxviral vectors have a proven safety record and can be used to incorporate multiple transgenes. Prior clinical trials with poxviral vaccines shown that immunologic tolerance self-antigens broken. Carcinoembryonic antigen (CEA) MUC-1 are overexpressed in substantial proportion of common solid carcinomas. The primary end point this study was vaccine safety, responses as secondary points.We report here pilot 25 patients treated regimen consisting the genes for CEA MUC-1, along triad...
Abstract Purpose: Identification of tumor antigens is essential in advancing immune-based therapeutic interventions cancer. Particularly attractive targets are those molecules that selectively expressed by malignant cells and also for progression. Experimental Design Results: We have used a computer-based differential display analysis tool mining sequence tag clusters the human Unigene database identified Brachyury as novel antigen. Brachyury, member T-box transcription factor family, key...
Mesenchymalization is a cellular and molecular program in which epithelial cells progressively lose their well-differentiated phenotype adopt mesenchymal characteristics. Tumor mesenchymalization occurs during the progression of cancer to metastatic disease, also associated with resistance multiple therapeutics, including killing by cytotoxic immune cells. Furthermore, tumor can evade destruction upregulating checkpoint molecule PD-L1, emerging research has found higher PD-L1 expression...
The complex signaling networks of the tumor microenvironment that facilitate growth and progression toward metastatic disease are becoming a focus potential therapeutic options. chemokine IL-8 is overexpressed in multiple cancer types, including triple-negative breast (TNBC), where it promotes acquisition mesenchymal features, stemness, resistance to therapies, recruitment immune-suppressive cells site. present study explores utility clinical-stage monoclonal antibody neutralizes (HuMax-IL8)...
Brachyury is a transcription factor of the T-box family typically expressed in notochord and chordoma. Some studies report brachyury as highly specific for chordoma, whereas others have concluded that many types common carcinomas by reverse polymerase chain reaction immunohistochemistry could be involved epithelial-mesenchymal transition metastatic process. In this study, we immunohistochemically evaluated 5229 different tumors nuclear expression using new rabbit monoclonal antibody...
The epithelial-mesenchymal transition (EMT) is emerging as a critical factor for the progression and metastasis of carcinomas, well drug resistance. T-box transcription Brachyury has been recently characterized driver EMT in human carcinoma cells. purpose this study was to characterize potential target lung cancer therapy.The expression evaluated by PCR immunohistochemistry tumors adult normal tissues. gene copy number promoter methylation status were analyzed tumor tissues with various...
The T-box transcription factor Brachyury, a molecule frequently detected in human cancers but seldom found normal adult tissue, has recently been characterized as driver of the epithelial-to-mesenchymal switch carcinomas. In current investigation, we present data demonstrating that two different lung carcinoma models expression Brachyury strongly correlates with increased vitro resistance to cytotoxic therapies, such chemotherapy and radiation. We also demonstrate treatment selects for tumor...
Aberrant expression of the T-box transcription factor brachyury in human carcinomas drives phenomenon epithelial-mesenchymal transition (EMT), a phenotypic modulation that facilitates tumor dissemination and resistance to conventional therapies, including chemotherapy radiotherapy. By generating isogenic cancer cell lines with various levels expression, we demonstrate high also significantly reduce susceptibility cells lysis by both antigen-specific T natural killer cells. Our results...